CSLLY News and Press, CSL Ltd ADR From 05/16/21

New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day p...

Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge Dr. Minnie Sarwal of NephroSant has been selected to receive the $25,000 Innovation Award PR Newswire NEW YORK , May 14, 2021 /PRNewswire/ -- Lyfebulb, a patient-emp...

CSL Behring Canada, a unit of CSL Limited (CSLLY) announced that HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), is now available throughout Canada.A subcutaneous C1 esterase inhibitor (C1-INH) treatment, HAEGARDA is indicated for the prevention of Hereditary Angioedema ((HAE...

CSL Behring, a subsidiary of CSL Limited ([[CSLLY]]) has completed the previously announced commercialization and license agreement with uniQure ([[QURE]] +4.7%) for etranacogene dezaparvovec (AMT-061), a gene therapy candidate targeting hemophilia B.The closing of the deal follows ...

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec - Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional leve...

LEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improveme...

Seqirus Presents New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age Seqirus Presents New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through ...

Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients The label update is based on open label extension data from the landmark PATH (Polyneuropathy A...

Grifols operates in the very attractive and lucrative plasma business. The plasma-supply chain has been disrupted by the pandemic but the situation should normalize with the vaccination. Even though some new medicines could potentially disrupt the market, we believe related fears ...

CSL Pharma, a division of CSL Limited (CSLLY), will not renew a supply agreement with Haemonetics (HAE) for the use  PCS2 Plasma Collection System devices and the purchase of  plasmapheresis kits.The agreement expires in June 2022 and accounted for $117M -- 11.8% -- of overall ...